SanazMemarzadehMDPhD
Obstetrics & Gynecology • Los Angeles, CAGynecologic Oncology
Professor, Gynecologic Oncologist Obstetrics & Gynecology, UCLA School of Medicine Director of the G.O. Discovery Laboratory
Dr. Memarzadeh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Avenue, 27-139 CHS
Los Angeles, CA 90095Phone+1 310-794-7274Fax+1 310-794-7274
Education & Training
University of California Los AngelesPh.D., Molecular Biology, 2003 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gynecologic Oncology, 2000 - 2003- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
University of Pittsburgh School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1998 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Super Doctors of Southern California Super Doctors, 2020-2023
- Los Angeles Top Doctors Top Doctors, 2018, 2020-2023
- Alpha omega alpha
- Join now to see all
Clinical Trials
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2016 Mar 02
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Start of enrollment: 2016 Jul 11
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Start of enrollment: 2018 May 14
Publications & Presentations
PubMed
- Commentary: Ovarian Cancer: Path to Effective Treatments.Anahid Jewett, Sanaz Memarzadeh, Kawaljit Kaur
Critical Reviews in Immunology. 2025-01-01 - PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.Grigor Varuzhanyan, Chia-Chun Chen, Jack Freeland, Tian He, Wendy Tran
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-03 - 2 citationsExploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.Kawaljit Kaur, Jashan Sanghu, Sanaz Memarzadeh, Anahid Jewett
Vaccines. 2024-06-18
Lectures
- Impact of Genetics on Personalizing Treatment of Gynecologic Cancers9/5/2019
- What are the signs of ovarian cancer?UCLA - 9/25/2018
- Ovarian Cancer: What You Need to KnowUCLA - 9/20/2018
- Join now to see all
Other
- Uterine sarcoma: Classification, clinical manifestations, and diagnosisMemarzadeh S, Mundt AJ, Berek JS
http://www.uptodate.com/contents/uterine-sarcoma-classification-clinical-manifestations-and-diagnosi
UpToDate, Wolters Kluwer Health - 2013-04-10
Press Mentions
UCLA Researchers Unite to Develop Immunotherapy They Hope Will Transform Ovarian Cancer TreatmentMarch 5th, 2025- UCLA Scientists Receive $17.4 Million in CIRM Grants to Advance Novel Stem-Cell Based TreatmentsMay 30th, 2024
- Common Causes of Sudden, Unexplained Weight GainSeptember 24th, 2020
- Join now to see all
Grant Support
- Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancersVA GREATER LOS ANGELES HEALTHCARE SYSTEM2024–2028
- Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancersVA GREATER LOS ANGELES HEALTHCARE SYSTEM2024–2028
- BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer CellsVA GREATER LOS ANGELES HEALTHCARE SYSTEM2023–2027
- BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer CellsVA GREATER LOS ANGELES HEALTHCARE SYSTEM2023–2027
Committees
- Member, National Institute of Health, Mechanisms of Cancer Therapeutics A Study Section
Other Languages
- Farsi, Spanish
External Links
- UCLA profilehttp://www.uclahealth.org/SanazMemarzadeh
- GO Discovery Labhttps://www.godiscoverylab.com
- Jonsson Comprehensive Cancer Centerhttps://cancer.ucla.edu/research/find-become-a-member/member-directory?id=417
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
